



PRESS RELEASE

Ceva Santé Animale Licenses MabGenesis' Therapeutic Antibodies for Canine Diseases

Yokohama, Japan, June 4, 2024 – Ceva Santé Animale S.A. (“Ceva”) and MabGenesis Inc. (“MabGenesis”) announced today that Ceva has exercised its option to an exclusive and worldwide license to MabGenesis' therapeutic antibodies, following a successful outcome of the research collaboration using MabGenesis' proprietary fully canine antibody library platform to explore novel antibody therapeutics. MabGenesis will receive an upfront payment and regular milestones payments. Ceva and MabGenesis are excited to lead the path to the future generation of antibody therapeutics in animal health.

About MabGenesis Inc.

MabGenesis is a biopharmaceutical startup that delivers first-in-class and best-in-class therapeutic monoclonal antibodies using technologies established by 30+ years of academic research. By using the innovative technology platform, high-quality phage display antibody libraries (MOURA Libraries) and efficient antibody isolation technology (IMPACT), MabGenesis makes it possible to isolate species-specific monoclonal antibodies rapidly and efficiently. MabGenesis is a private company headquartered in Yokohama, Japan. For more information, visit <https://mabgenesis.com/en>

MabGenesis Inc. press contact

Yuichiro Shibazaki – Chief Business Officer
Email: info@mabgenesis.com
Phone: + 81 80 5926 4677

About Ceva Santé Animale S.A.

Ceva Santé Animale (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines and animal welfare products, pharmaceutical solutions for farm and companion animals, as well as equipment and services to provide the best experience for our customers. With more than 7,000 employees located in 47 countries, Ceva strives daily to bring to life its vision as a One Health company: “Together, beyond animal health”. 2023 turnover: €1.6 billion. For more information, visit www.ceva.com

Ceva Sante Animale press contact

Emilie Barrail – Group head of external communication
Email: emilie.barrail@ceva.com
Phone: + 33 7 85 61 81 15